An ERMI lawsuit can mean one of two very different cases. The first is a proposed class action filed in June 2026 against ERMI, LLC, an Atlanta medical device company, over a data breach that exposed personal and health information belonging to more than 9,000 people. The second is the running courtroom fight over the Environmental Relative Moldiness Index, an EPA-developed mold test that also goes by the initials ERMI and that plaintiffs sometimes use as evidence in mold-injury cases. The two have nothing to do with each other, and which one applies to you depends on whether you received a breach-notification letter from ERMI, LLC or are dealing with a mold claim.
The ERMI, LLC Data Breach Class Action
ERMI, LLC designs non-surgical rehabilitation devices, including its Flexionater joint-therapy line, and works with physicians, physical therapists, the Veterans Affairs system, and workers’ compensation programs. In May 2026, the company disclosed that unauthorized access to a limited number of employee email accounts had exposed patient data.
According to the company’s disclosure, the intrusion ran from approximately February 15 to August 14, 2025. ERMI says it detected the unauthorized activity on or about July 25, 2025, and finished reviewing the affected mailboxes around April 17, 2026. The data potentially exposed includes:
- Social Security numbers
- Driver’s license numbers
- Passport numbers
- Dates of birth
- Login credentials
- Financial information
- Medical information
- Health insurance information
ERMI mailed notification letters to affected individuals on May 26, 2026, and offered complimentary credit monitoring, credit reports, and credit score services through Cyberscout, a TransUnion subsidiary. One investigation summary put the number of affected individuals at more than 9,000.
By early June 2026, a proposed class action had been filed in the U.S. District Court for the Northern District of Georgia. The complaint alleges that ERMI failed to protect patients’ protected health information, including diagnostic treatment data and provider names. Several other law firms have opened parallel investigations and are looking for individuals willing to serve as class representatives in additional suits. The case is in its early stages, and no settlement or ruling has been reached.
What to Do If You Got a Notification Letter
If you received a breach notice from ERMI, LLC, the letter itself explains how to enroll in the credit monitoring and identity protection services the company is offering through Cyberscout. Enrollment does not waive any legal rights. Individuals who want to be considered as potential class representatives, or who simply want to be kept informed about the litigation, can contact one of the law firms investigating the breach; those investigations are separate from the case already on file in the Northern District of Georgia and may produce additional complaints.
The EPA’s Mold Index in Court
The other ERMI is the Environmental Relative Moldiness Index, a mold-measurement tool developed by EPA researchers led by microbiologist Stephen Vesper and introduced in a 2007 paper. It analyzes household dust for the DNA of 36 indicator mold species and produces a single score that ranks a home’s mold burden against a national dataset of 1,096 homes surveyed in the 2006 HUD American Healthy Homes Survey. Twenty-six of the species are associated with water damage; the other ten are common indoor molds. The EPA licenses the underlying technology to commercial labs in the United States, Germany, and the United Kingdom, which sell ERMI testing to homeowners, inspectors, and litigants.
The EPA’s own position is narrow. The agency says ERMI is “not recommended for use except as a research tool” and, as of a September 2025 update to its website, still classifies it as a research instrument rather than a validated method for making decisions about individual homes.
Why the Test Gets Challenged
In August 2013, the EPA’s Office of Inspector General issued Report No. 13-P-0356, which found that licensees’ marketing could mislead consumers into believing ERMI carried EPA endorsement and that a since-removed EPA webpage had suggested the technology was validated for public use. The OIG concluded the public could “make inappropriate decisions or take unnecessary actions” based on ERMI results. The EPA acknowledged that neither ERMI nor the underlying Mold-Specific Quantitative Polymerase Chain Reaction method had been peer-reviewed or validated for public use, removed the problematic page, and agreed to publish a fact sheet spelling out the tool’s limitations.
Independent researchers and industrial hygienists have added technical criticisms that surface in litigation:
- ERMI reports DNA concentration per gram of dust, not per unit of surface area, so two homes with the same score can carry very different total exposures.
- Mold is unevenly distributed, and experts have argued a reliable sample might require more than 25 random collections in a single environment.
- The original ERMI protocol used a standardized five-minute vacuum sample over two square meters of carpet, but many commercial kits use an electrostatic cloth instead. Vesper himself has said the cloth “is not a standardized method of dust collection and is not a replacement for the standard vacuum sampling method.” A 2021 study found the two methods agreed on a simple moldiness yes-or-no about 96 percent of the time but did not produce interchangeable numerical scores.
- One peer-reviewed study found ERMI had a 28 percent error rate in predicting patient health outcomes.
- ERMI does not identify where mold is growing, distinguish active growth from historical dust, or pinpoint moisture sources.
Dr. Kevin Oshima, an EPA scientist, has said the agency cannot vouch for the accuracy of commercial applications of the test because it lacks a multi-laboratory validation study.
How ERMI Actually Plays Out in Mold Cases
Despite the EPA’s disclaimers, plaintiffs do introduce ERMI results in mold cases. Dr. Ritchie Shoemaker, who developed a treatment protocol for what he calls Chronic Inflammatory Response Syndrome, has advocated for using ERMI and a related metric called HERTSMI-2 to judge whether a water-damaged building is safe to reoccupy. In a Brooklyn case styled Holland, a Frye challenge was raised against Shoemaker’s testimony; the trial judge declined to exclude it, and the case settled before he took the stand.
No published court opinion appears to have squarely ruled on whether ERMI results satisfy the Daubert or Frye standards for scientific evidence. That leaves both sides room to fight. Defense attorneys are expected to lean on the 2013 OIG findings to argue the test lacks the validation courts require, and one legal analysis predicted the OIG report will be deployed by “mold defense consultants” against ERMI-based claims.
The larger evidentiary problem is that there are no federal standards or threshold limit values for indoor mold exposure. The EPA itself states that mold sampling “cannot be used to check a building’s compliance with federal mold standards” because no such standards exist. Professional bodies including the American Industrial Hygiene Association and the American Conference of Governmental Industrial Hygienists publish sampling guidance, but courts and regulators have not adopted uniform rules for what level of mold contamination counts as a health hazard. In practice, that means judges exercise broad discretion over what mold-test evidence comes in, and the choice of testing method often turns on what a particular court will accept rather than on scientific consensus.